PMV Pharmaceuticals, Inc. (PMVP) earnings
PMVP earnings moved a median of +2.44% by the close. Quarterly and annual PMVP reports and results, each read against the price at its own news timestamp. Back to the PMVP overview →
21 measured PMVP earnings events.
Where these PMVP earnings landedvs 21 measured PMVP earnings reactions
| Middle 50% of PMVP earnings reactions | -1.87% to +3.85% |
|---|---|
| Median reaction (to close) | +2.44% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 PMVP earnings events with a measured close landed between -1.87% and +3.85%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q PMV Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +2.44% | |
| PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights | Press release | +0.00% | +2.44% | |
| Form 10-Q PMV Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -0.69% | -1.39% | |
| PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights | Press release | -0.69% | -1.39% | |
| Form 10-K PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.63% | +0.61% | |
| Form 10-Q PMV Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +2.22% | +5.18% | |
| PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights | Press release | +2.22% | +5.18% | |
| Form 10-Q PMV Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -1.34% | -2.69% | |
| PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights | Press release | -1.34% | -2.69% | |
| Form 10-Q PMV Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +3.85% | |
| PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | Press release | +0.00% | +3.85% | |
| Form 10-K PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -2.21% | -2.94% | |
| Form 10-Q PMV Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -0.60% | +7.23% | |
| PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results | Press release | -0.60% | +7.23% | |
| Form 10-Q PMV Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | -2.01% | -2.01% | |
| PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial | Press release | -2.01% | -2.01% | |
| Form 10-Q PMV Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -1.17% | -1.87% | |
| PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights | Press release | -1.17% | -1.87% | |
| Form 10-K PMV Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +2.78% | +4.17% | |
| Form 10-Q PMV Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.27% | +2.70% | |
| PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights | Press release | +0.27% | +2.70% |
Keep exploring
More PMVP: analyst actions → · SEC filings → · PMVP overview →